IFNL3 and cryohydrocytosis: Because both fibrosis and the IFNL3 non-CC genotype are two well-documented negative factors for SVR in interferon-based therapy [2], the reliability of this prospective study of 474 CHC patients who had completed a course of anti-HCV therapy is assured by the fact that the non-SVR patients had significantly more advanced fibrosis but a lower prevalence of the IFNL3 CC genotype than the SVR patients.